BACKGROUND: Epidermal growth factor receptor (EGFR)-targeted therapy has been extensively assessed in human cancer treatment. We appraised the possible role of tyrosine kinase inhibitors (TKIs) in areca quid (AQ)-associated oral cavity squamous cell carcinomas (OSCCs) by examining EGFR protein overexpression and its tyrosine kinase domain mutations. METHODS: EGFR overexpression was evaluated by immunohistochemical staining, and tyrosine kinase mutations was determined by direct sequencing of DNAs from 172 OSCC tumors. RESULTS: Overexpression of EGFR was found in 27.9% (48 of 172) of the OSCCs and was associated with lymph node metastasis (p = .013) and extracapsular spread (p = .022). Only 1 (0.58%) OSCC displayed somatic EGFR mutation but in a silent form (T725T, ACG-->ACA). CONCLUSION: EGFR-targeted therapy might have some potential in AQ-associated OSCCs for their EGFR frequently overexpressed, although EGFR mutations were rare. However, the feasibility of TKIs in AQ-associated OSCCs needs further clinical testing. Copyright 2009 Wiley Periodicals, Inc.
BACKGROUND:Epidermal growth factor receptor (EGFR)-targeted therapy has been extensively assessed in humancancer treatment. We appraised the possible role of tyrosine kinase inhibitors (TKIs) in areca quid (AQ)-associated oral cavity squamous cell carcinomas (OSCCs) by examining EGFR protein overexpression and its tyrosine kinase domain mutations. METHODS:EGFR overexpression was evaluated by immunohistochemical staining, and tyrosine kinase mutations was determined by direct sequencing of DNAs from 172 OSCC tumors. RESULTS: Overexpression of EGFR was found in 27.9% (48 of 172) of the OSCCs and was associated with lymph node metastasis (p = .013) and extracapsular spread (p = .022). Only 1 (0.58%) OSCC displayed somatic EGFR mutation but in a silent form (T725T, ACG-->ACA). CONCLUSION:EGFR-targeted therapy might have some potential in AQ-associated OSCCs for their EGFR frequently overexpressed, although EGFR mutations were rare. However, the feasibility of TKIs in AQ-associated OSCCs needs further clinical testing. Copyright 2009 Wiley Periodicals, Inc.
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Adriana R Ribeiro; Andréia P Guimarães; Ludmila T Chinen; Clóvis A P Lopes; Vladmir C C de Lima Journal: Int J Clin Oncol Date: 2014-05-27 Impact factor: 3.402
Authors: Daniel S W Tan; Weining Wang; Hui Sun Leong; Pui Hoon Sew; Dawn P Lau; Fui Teen Chong; Sai Sakktee Krisna; Tony K H Lim; N Gopalakrishna Iyer Journal: BMC Cancer Date: 2014-09-19 Impact factor: 4.430